Trial Profile
Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 08 Sep 2015
Price :
$35
*
At a glance
- Drugs Elotuzumab (Primary)
- Indications Multiple myeloma
- Focus Expanded access; Therapeutic Use
- 08 Sep 2015 New trial record